ECM
PTGX icon

Element Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Element Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-19,663
Closed -$202K – 837
2018
Q3 		$202K Sell
19,663
-35,054
-64% -$302K ﹤0.01% 770
2018
Q2 		$368K Buy
54,717
+34,371
+169% +$264K 0.01% 480
2018
Q1 		$175K Buy
+20,346
New +$383K ﹤0.01% 711

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Element Capital Management's PTGX Position: Q4 2018 in Review

Element Capital Management sold out of Protagonist Therapeutics (PTGX) in Q4 2018, closing a stake of 19,663 shares — an estimated $202K sold.

Element Capital Management first reported a position in PTGX in Q1 2018 and held it in 3 quarters. The position peaked at $368K in Q2 2018. 66 funds tracked by Wall St. Rank hold PTGX as of Q4 2018.

  • Element Capital Management reported no remaining Protagonist Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Element Capital Management sold 19,663 Protagonist Therapeutics shares in Q4 2018, an estimated $202K.
  • Element Capital Management first reported a position in Protagonist Therapeutics in Q1 2018 and held it in 3 quarters.
  • Element Capital Management's Protagonist Therapeutics position peaked at $368K in Q2 2018.
  • 66 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2018.

Based on Element Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.